Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memory Pharmaceuticals
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of schizophrenia (any subtype), assessed using a structured interview.
At least one month on the same dose of antipsychotic medication.
Clinically stable, as judged by the investigator, and in a non-acute phase for at least 12 weeks.
Able to provide informed consent.
Fluent in English.
Smokers and non-smokers.
You may not be if
First 3 years of schizophrenia diagnosis.
Current risk of suicide, or history of suicidal behavior within the last 6 months.
Hospitalized for psychiatric symptoms in the past 3 months.
Other psychiatric diagnoses.
Substance abuse/dependence (other than nicotine or caffeine) within the last 6 months according.
Nicotine replacement therapy, smoking cessation medications or remedies, including Varenicline (Chantix).
Clareo Health | Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
